Ignite Creation Date:
2024-05-06 @ 3:50 PM
Last Modification Date:
2024-10-26 @ 1:58 PM
Study NCT ID:
NCT04775446
Status:
COMPLETED
Last Update Posted:
2022-02-04
First Post:
2021-02-01
Brief Title:
Evaluation of the ClinicalBiological Characteristics Efficacy and Safety of Patients With Malignant Pleural Mesothelioma Treated by Immunotherapy
Sponsor:
Centre Hospitalier Intercommunal Creteil
Organization:
Centre Hospitalier Intercommunal Creteil
Study Overview
Official Title:
Multicentre Observational Study Evaluating the ClinicalBiological Characteristics Efficacy and Safety of Patients With Malignant Pleural Mesothelioma Treated by Immunotherapy in Real Life Setting
Status:
COMPLETED
Status Verified Date:
2022-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
MESOIMMUNE
Brief Summary:
The objective of this multicentre descriptive analysis is to describe the clinical and biological characteristics of patients who have received Programmed cell death 1 anti-PD1 PDL1 Programmed death-ligand 1 PDL1 immunotherapy outside of a clinical trial in terms of efficacy and safety
Detailed Description:
Immunotherapy is now an option in the treatment of malignant pleural mesothelioma A French study Mesothelioma Avastin plus Pemetrexed-cisplatin Study 2 MAPS 2 prospective in 2nd line or more found 40 and 52 disease control rate with respectively an anti-PD1 antibody or a combo of anti-PD1 and Cytotoxic T-Lymphocyte-Associated protein 4 anti-CTLA4 Safety was rather good with 14 and 26 grade 3-4 in the Nivolumab and combo group respectively
Thanks to this trial and data from the literature Programmed cell death 1 anti-PD1 PDL1 Programmed death-ligand 1 PDL1 immunotherapy became an option in the treatment of malignant pleural mesothelioma after validation by a multidisciplinary meeting
The objective of this multicentre descriptive analysis is to describe the clinical and biological characteristics of patients who have received anti-PD1PDL1 immunotherapy outside of a clinical trial in terms of efficacy and safety
Thanks to this trial and data from the literature Programmed cell death 1 anti-PD1 PDL1 Programmed death-ligand 1 PDL1 immunotherapy became an option in the treatment of malignant pleural mesothelioma after validation by a multidisciplinary meeting
The objective of this multicentre descriptive analysis is to describe the clinical and biological characteristics of patients who have received anti-PD1PDL1 immunotherapy outside of a clinical trial in terms of efficacy and safety
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None